Suspended

Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill

What is being tested

AN 69 ST hemofilter

+ AN 69 hemofilter

Device

Who is being recruted

Urogenital Diseases+19

+ Cardiovascular Diseases

+ Female Urogenital Diseases and Pregnancy Complications

From 18 to 90 Years

+7 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

Study Start: January 2012

See protocol details

Summary

Principal SponsorZhongda Hospital

Study ContactQiu XiaohuaMore contacts

Last updated: January 15, 2014

Sourced from a government-validated database.Claim as a partner

Study start date: January 1, 2012

Actual date on which the first participant was enrolled.

Compared with AN69 hemofilter, AN69 ST hemofilter may prolong the time of hemofilter and decrease the quantity of heparin during continuous renal replacement therapy in critically ill.

NCT01823484

Principal SponsorZhongda Hospital

Study ContactQiu XiaohuaMore contacts

Last updated: January 15, 2014

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

40 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 90 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesCardiovascular DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsInfectionsInflammationKidney DiseasesPathologic ProcessesShockPathological Conditions, Signs and SymptomsUrologic DiseasesVascular DiseasesEmbolism and ThrombosisSystemic Inflammatory Response SyndromeSepsisDisease AttributesRenal InsufficiencyFemale Urogenital DiseasesMale Urogenital DiseasesShock, SepticThrombosisCritical IllnessAcute Kidney Injury

Criteria

3 inclusion criteria required to participate

admitted to ICU and need CRRT

age > 18 years old

anticipated survival time > 72h

4 exclusion criteria prevent from participating

allergy to hemofilter or heparin

heparin associated thrombocytopenia

pregnancy or lactation

using other anticoagulate drugs

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Use AN 69 ST hemofilter during CRRT

Group II

Active Comparator

Use AN 69 hemofilter during CRRT

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Xiaohua Qiu

Nanjing, ChinaOpen Xiaohua Qiu in Google Maps

SuspendedOne Study Center